Current Report Filing (8-k)
October 14 2021 - 12:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 13, 2021
GBS
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-39825
|
|
82-1512711
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
420
Lexington Ave, Suite 300
New
York, NY 10170
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: Telephone: (646) 828-8258
708
Third Avenue, 6th Floor, New York, NY 10017
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value
|
|
GBS
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
8.01 Other Events
On
October 13, 2021 GBS, Inc. (the “Company”) issued a press release announcing that its pre-submission package is with the
United States Food and Drug Administration (FDA). A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference. The foregoing disclosure is qualified in its entirety by the full text of the press release.
Item
9.01. Financial Statements and Exhibits.
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
October 14, 2021
|
GBS,
INC.
|
|
|
|
|
By:
|
/s/
Harry Simeonidis
|
|
Name:
|
Harry
Simeonidis
|
|
Title:
|
Chief
Executive Officer and President
|
GBS (NASDAQ:GBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
GBS (NASDAQ:GBS)
Historical Stock Chart
From Jul 2023 to Jul 2024